Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Zhejiang Chinese Medical University | China

Author Profile

Scopus

Biography of Hong-Hong Zhu, MD, MSc, PhD – Professor of Extraordinary Ability πŸŽ“πŸŒ

🎯 Current Role: Leader in Medical Research

Dr. Hong-Hong Zhu is the Head of the Center for Medical Research at Zhejiang Chinese Medical University Affiliated Four-Province-Bordering Hospital of Traditional Chinese Medicine (Quzhou Hospital of TCM). Her leadership in medical research spans over three decades.

πŸ“œ Educational Background

  • Ph.D. in Epidemiology from Johns Hopkins University (JHU) Bloomberg School of Public Health (2007)
  • Postdoctoral Training at the U.S. National Institutes of Health (NIH)
  • MD & Master’s Degree in Medicine from Zhejiang University
  • M.Sc. from Clemson University

πŸ’‘ Key Contributions: Breast Cancer Etiology Pioneer

Dr. Zhu was the first to propose the Synergistic Interaction Theory for breast cancer, linking environmental carcinogens and exogenous hormone use. Her work has significantly advanced the understanding of cancer causes.

πŸ”¬ Innovator in Colorectal Cancer Prevention

With 32 years of research in colorectal cancer prevention, Dr. Zhu and her team developed cost-effective screening methods that have saved millions of lives worldwide.

πŸ† Academic Achievements and Awards

  • 135 Publications in esteemed journals
  • 35 Awards, including:
    • Best Poster Award (NIH) for breast cancer research (2006)
    • Delta Omega Honor from the U.S. National Public Health Honor Society (2007)
    • Second Place in Scientific Competition in Epidemiology and Public Health (2007)
    • Professor of Extraordinary Ability (2015)
    • Sigma Xi Scientific Research Honor (2024)

πŸ“š Editor and Peer Reviewer

  • Editor-in-Chief of the Journal of GHR (since 2015)
  • Peer Reviewer for academic journals for over 20 years
  • Grant Reviewer for the U.S. Department of Health and Human Services (12 years)

Dr. Hong-Hong Zhu’s contributions to medical research have made her a global figure in epidemiology and cancer prevention.

πŸ” Conclusion

With over three decades of research in epidemiology and disease prevention, Dr. Hong-Hong Zhu has made groundbreaking contributions in breast and colorectal cancer research. Her innovative approaches to cancer screening and prevention have been life-saving on a global scale. She remains a recognized leader in public health, continuing to inspire through her research, publications, and numerous honors. 🌟

 

πŸ“ŠπŸ”¬NOTABLE PUBLICATION:

 

  • Combining FITs and HRFQ with colonoscopy improve the cost-effectiveness of a 9-year mass colorectal cancer screening program
    Authors: Cai, S.-R., Huang, Y.-Q., Li, Q.-R., Yang, J.-H., Zheng, S.
    Journal: ESMO Open
    Year: 2024

 

  • Sex difference in alcohol consumption associated with colorectal cancer risk in Quzhou, China: A nested case-control study
    Authors: Lai, S.-M., Zhu, H.-H., Gan, Z.-J., Wang, Z.-C., Liao, X.-F.
    Journal: Preventive Medicine Reports
    Year: 2024

 

  • Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years
    Authors: Zhu, H.-H., Sun, G.-Q., Wu, J.-Y., Wang, Z.-C., Liao, X.-F.
    Journal: Frontiers in Immunology
    Year: 2023

Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de CÒncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021